Red Rice Yeast in Low-density Lipoprotein (LDL) Lowering: an Efficacy Study

Sponsor
Saint-Joseph University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03607383
Collaborator
(none)
40
1
2
26.7
1.5

Study Details

Study Description

Brief Summary

Red yeast rice is a source of active compounds in reducing LDL levels with practically no side effects. Molval Fort is a natural product available in the Lebanese market with a combination of red yeast rice extracts, EPA/DHA and coenzyme Q10.

The investigators are conducting this study to explore the effect of red yest rice extracts based product on LDL and its side effects in a sample of primary care Lebanese patients.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Red yeast rice is a source of active compounds in reducing LDL levels with practically no side effects. Studies performed on American and Chinese populations have shown positive results. These studies need confirmation in different populations. Molval Fort is a natural product available in the Lebanese market with a combination of red yeast rice extracts, EPA/DHA and coenzyme Q10. The investigators are conducting this study to explore the effect of red yest rice extracts based product on LDL and its side effects in a sample of primary care Lebanese patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Red Rice Yeast in Low-density Lipoprotein (LDL) Lowering: an Efficacy Study
Actual Study Start Date :
Feb 7, 2018
Anticipated Primary Completion Date :
Apr 30, 2020
Anticipated Study Completion Date :
Apr 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Red rice yeast group

Red rice yeast based product will be provided under the brand name Molval Fort, one pill a day, for 8 weeks, for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions

Drug: Red Rice Yeast Extract
adults requiring moderate intensity treatment will be provided red rice yeast extracts or statins, depending on the randomization; followed for compliance and adverse effects check, and reevaluated in a final visit with blood test after 8 weeks

Active Comparator: Statin group

Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks

Drug: Statin
Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks

Outcome Measures

Primary Outcome Measures

  1. LDL reduction [eight weeks]

    after an eight week treatment, cholesterol LDL levels' reduction is compared in the two groups

Secondary Outcome Measures

  1. incidence of side effects [eight weeks]

    after eight weeks of treatment, the incidence of side effects is studied among the red rice yeast group

Other Outcome Measures

  1. physician and patient satisfaction [eight weeks]

    physician and patient satisfaction will be evaluated by a single question questionnaire: Were you satisfied by the treatment?

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adult patient (>18 years)

  • Indication to mild or moderate statin based on AHA 2013 guidelines

  • Treatment naïve

Exclusion Criteria:
  • Allergy to rice

  • Renal or hepatic terminal disease

  • Any contra indication to statin treatment

  • Pregnancy wish during study period

  • Familial hypercholesterolemia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Saint Anthony Primary Care Center Jdeide Lebanon

Sponsors and Collaborators

  • Saint-Joseph University

Investigators

  • Principal Investigator: Marouan Zoghbi, Hôtel Dieu de France Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Saint-Joseph University
ClinicalTrials.gov Identifier:
NCT03607383
Other Study ID Numbers:
  • RRY2018
First Posted:
Jul 31, 2018
Last Update Posted:
Oct 8, 2019
Last Verified:
Oct 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Saint-Joseph University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 8, 2019